<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty-four patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, 23 men and 11 women, aged between 47 and 80 years, with <z:hpo ids='HP_0000001'>all</z:hpo> types of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> were treated with <z:chebi fb="0" ids="6067">13-cis-retinoic acid</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The dose of <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> ranged between 10 and 60 mg/m2/daily and was administered in combination with vitamin E to diminish side effects </plain></SENT>
<SENT sid="2" pm="."><plain>The duration of treatment was 3 months to 5 years </plain></SENT>
<SENT sid="3" pm="."><plain>Partial remission was achieved in 4 patients, 1 with RA type, 2 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and 1 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Survival ranged from 1 to 5 years </plain></SENT>
<SENT sid="5" pm="."><plain>Patients who received <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> developed mild side effects </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, the administration of <z:chebi fb="0" ids="6067">13-cis-retinoic acid</z:chebi> improves the hematological picture in a small number of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (11.7%) </plain></SENT>
</text></document>